Department of Pediatrics, Furano Kyokai Hospital, Furano, Japan.
Department of Clinical Laboratory, Furano Kyokai Hospital, Furano, Japan.
Pediatr Int. 2022 Jan;64(1):e15169. doi: 10.1111/ped.15169.
Previous reports have not clarified the difference in clinical efficacy between baloxavir and oseltamivir against influenza.
A prospective observational study was performed during 2017-2018, 2018-2019, and 2019-2020 influenza seasons. The primary endpoint of this study was to compare the duration of fever between patients who received baloxavir and those who received oseltamivir.
A total of 235 influenza-infected patients (3-18 years of age), including 91 who received oseltamivir and 144 who received baloxavir, were enrolled. The proportions of influenza A(H3N2) virus, influenza A(H1N1)pdm09 virus, and influenza B virus-infected patients were 31.5%, 42.6%, and 26.0%, respectively. Patients who received oseltamivir were significantly younger than those who received baloxavir. Univariate analyses showed that the duration of fever was shorter with baloxavir than with oseltamivir against influenza virus overall, influenza A virus, influenza B virus, and influenza A(H1N1)pdm09 virus, but not for influenza A(H3N2) virus. In multivariate analyses, hazard ratios for influenza virus overall (0.53 [95% CI, 0.38-0.73]), influenza B virus (0.16 [95% CI, 0.07-0.41]), and influenza A(H1N1)pdm09 virus (0.55 [95% CI, 0.32-0.93]) were significantly lower in the patients who received baloxavir than those who received oseltamivir. However, the differences between influenza A virus and influenza A(H3N2) virus were not significant between the two groups.
For influenza virus overall, influenza B virus, and influenza A(H1N1)pdm09 virus, baloxavir treatment resulted in shorter duration of fever than oseltamivir treatment, but not for influenza A virus and influenza A(H3N2) virus.
之前的报告并未阐明巴洛沙韦与奥司他韦治疗流感的临床疗效差异。
在 2017-2018、2018-2019 和 2019-2020 流感季节进行了一项前瞻性观察性研究。本研究的主要终点是比较接受巴洛沙韦治疗和接受奥司他韦治疗的患者的发热持续时间。
共纳入 235 例流感感染患者（3-18 岁），其中 91 例接受奥司他韦治疗，144 例接受巴洛沙韦治疗。甲型流感病毒（H3N2）、甲型流感病毒（H1N1)pdm09 病毒和乙型流感病毒感染患者的比例分别为 31.5%、42.6%和 26.0%。接受奥司他韦治疗的患者明显较接受巴洛沙韦治疗的患者年轻。单因素分析显示，巴洛沙韦治疗流感病毒总体、甲型流感病毒、乙型流感病毒和甲型流感病毒（H1N1)pdm09 病毒的发热持续时间均短于奥司他韦，但对甲型流感病毒（H3N2）病毒无影响。多因素分析显示，流感病毒总体（0.53[95%CI，0.38-0.73]）、乙型流感病毒（0.16[95%CI，0.07-0.41]）和甲型流感病毒（H1N1)pdm09 病毒（0.55[95%CI，0.32-0.93]）的风险比在接受巴洛沙韦治疗的患者中显著低于接受奥司他韦治疗的患者。然而，两组之间甲型流感病毒和甲型流感病毒（H3N2）病毒的差异无统计学意义。
对于流感病毒总体、乙型流感病毒和甲型流感病毒（H1N1)pdm09 病毒，巴洛沙韦治疗的发热持续时间短于奥司他韦治疗，但对甲型流感病毒和甲型流感病毒（H3N2）病毒无影响。
